CA
TRIB

Clearstead Advisors’s Trinity Biotech TRIB Stock Holding History

Clearstead Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$8.8K – 2312
2024
Q4 		$8.8K Buy
+10,000
New +$13.4K ﹤0.01% 1606

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return

Clearstead Advisors's TRIB Position: Q1 2025 in Review

Clearstead Advisors sold out of Trinity Biotech (TRIB) in Q1 2025, closing a stake of 10,000 shares — an estimated $8.8K sold.

Clearstead Advisors first reported a position in TRIB in Q4 2024 and held it in 1 quarter. The position peaked at $8.8K in Q4 2024. 27 funds tracked by Wall St. Rank hold TRIB as of Q1 2025.

  • Clearstead Advisors reported no remaining Trinity Biotech position as of Q1 2025 after selling out during the quarter.
  • Clearstead Advisors sold 10,000 Trinity Biotech shares in Q1 2025, an estimated $8.8K.
  • Clearstead Advisors first reported a position in Trinity Biotech in Q4 2024 and held it in 1 quarter.
  • Clearstead Advisors's Trinity Biotech position peaked at $8.8K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2025.

Based on Clearstead Advisors's 13F filing for Q1 2025, filed 13 May 2025.